Livzon Pharmaceutical Group Inc.

SZSE:000513.SZ

32.51 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419921991
Revenue 12,278.52312,629.57912,063.86310,520.419,384.6968,860.6568,530.9697,651.7756,620.5175,544.2344,618.683,943.5253,162.9152,726.7192,595.8472,058.6411,748.1081,510.0511,626.1461,554.7881,811.9141,601.2061,395.7921,178.5531,133.82899.045822.213721.128682.735600.07699.718695.919
Cost of Revenue 4,921.9274,461.2834,253.0873,673.7113,391.7283,359.6553,083.0812,747.7882,575.3312,142.9111,694.6151,569.6881,397.9371,286.4851,231.9861,116.318973.621806.016906.231791.508914.621894.467741.367634.763622.816580.295526.104475.573466.509423.936571.84578.547
Gross Profit 7,356.5968,168.2967,810.7766,846.6995,992.9685,501.0015,447.8884,903.9874,045.1863,401.3232,924.0652,373.8371,764.9781,440.2341,363.861942.323774.488704.035719.915763.279897.293706.739654.425543.791511.004318.75296.109245.555216.226176.134127.878117.372
Gross Profit Ratio 0.5990.6470.6470.6510.6390.6210.6390.6410.6110.6130.6330.6020.5580.5280.5250.4580.4430.4660.4430.4910.4950.4410.4690.4610.4510.3550.360.3410.3170.2940.1830.169
Reseach & Development Expenses 973.1891,426.5231,145.702884.095732.892548.973427.152291.119222.031189.5146.98124.0400000000000000000000
General & Administrative Expenses 654.274656.857241.85253.523261.466264.772260.385201.224184.966124.629142.719351.031297.63265.89236.727197.767194.614230.855238.241213.292235.114196.794172.191149.276189.59982.76669.65141.63722.00625.20313.2229.893
Selling & Marketing Expenses 3,598.1533,887.3923,883.8753,075.8693,093.223,267.283,265.173,070.3712,541.6752,208.2191,810.7471,441.654970.891648.046546.253377.277264.866312.118345.651417.779515.908372.506371.299326.855321.165222.9176.566139.879117.21459.96731.85424.125
SG&A 4,170.5454,544.254,125.7253,329.3913,354.6863,532.0523,525.5553,271.5952,726.6412,332.8481,953.4671,792.6851,268.521913.936782.98575.044459.481542.973583.892631.071751.022569.3543.489476.131510.765305.666246.217181.515139.2285.1745.07734.018
Other Expenses -291.022-36.88351.717318.208320.443142.43368.634130.173121.13168.87138.56342.64233.56818.0877.4427.9486.949-28.5713.1122.6574.60813.1427.5353.44120.69355.95933.01529.42616.2189.4451.411-0.571
Operating Expenses 5,434.7555,933.8925,623.1444,531.6944,408.024,395.9854,236.2073,915.3273,228.9862,741.9342,306.5631,847.2311,309.252922.794788.709579.509463.546546.779588.01633.158755.701572.188546.699477.449511.402306.055246.319181.515139.2285.28852.29741.274
Operating Income 1,921.8412,350.5562,266.992,500.4491,729.8531,274.4965,657.808876.48692.799584.509590.557518.753429.745516.415583.27899.604613.756218.41131.736157.553158.836113.652107.86735.319-2.3849.00437.58967.53373.557106.30561.07659.966
Operating Income Ratio 0.1570.1860.1880.2380.1840.1440.6630.1150.1050.1050.1280.1320.1360.1890.2250.0480.3510.1450.0810.1010.0880.0710.0770.03-0.0020.010.0460.0940.1080.1770.0870.086
Total Other Income Expenses Net 402.365-20.005-21.301-11.013-2.311311.6584,513.24216.401-8.279-7.36411.43833.7067.42516.22714.267-257.16309.03722.363-2.57819.04810.366-38.203-19.353-34.58915.99948.31719.8332.86810.72119.828-13.578-16.702
Income Before Tax 2,324.2062,330.5512,245.6892,489.4361,727.5421,416.6745,724.9231,005.061807.921652.025628.94560.313463.151533.667589.418105.654619.979184.729132.087154.69157.701111.571101.88835.25616.95562.98870.11296.93388.751113.21262.24559.395
Income Before Tax Ratio 0.1890.1850.1860.2370.1840.160.6710.1310.1220.1180.1360.1420.1460.1960.2270.0510.3550.1220.0810.0990.0870.070.0730.030.0150.070.0850.1340.130.1890.0890.085
Income Tax Expense 485.066375.01293.588358.109265.965234.961,237.22175.146148.35898.403104.95485.0975.35381.17775.62432.74796.59835.40315.81519.94536.23425.25527.1759.3527.91915.94415.53910.2587.65710.2933.0041.613
Net Income 1,953.6511,909.4081,775.6831,714.911,302.8751,082.1754,428.685784.354622.641515.978487.502441.672359.37418.181481.57852.073508.451139.15107.892124.05892.20161.94350.39210.3761.64740.83343.19681.43980.153101.10859.24157.782
Net Income Ratio 0.1590.1510.1470.1630.1390.1220.5190.1030.0940.0930.1060.1120.1140.1530.1860.0250.2910.0920.0660.080.0510.0390.0360.0090.0010.0450.0530.1130.1170.1680.0850.083
EPS 2.12.041.91.831.391.164.780.90.740.610.580.520.430.490.560.060.580.180.150.180.130.090.0710.0140.0020.0040.060.140.140.190.0720.07
EPS Diluted 2.12.041.91.831.391.164.770.890.730.610.580.520.430.490.560.060.580.180.150.180.130.090.0710.0140.0020.0040.060.140.140.190.0720.07
EBITDA 2,788.2193,277.1422,855.1212,974.8852,175.7061,837.8285,978.6461,503.8261,259.15989.822853.622759.676671.629666.509649.526576.701676.295323.989247.552241.914251.291204.098192.062118.40141.96144.78249.7964.03977.00590.84675.58176.098
EBITDA Ratio 0.2270.2590.2370.2830.2320.2070.7010.1970.190.1790.1850.1930.2120.2440.250.280.3870.2150.1520.1560.1390.1270.1380.10.0370.050.0610.0890.1130.1510.1080.109